ConductScience.org, home

Paper3858013

Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Hill BT and 3 others. Cancer Chemother Pharmacol, 1985. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Papers, record 3858013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3858013

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1985
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
1.3
iCite
Revised in PubMed
2019-08-29
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hill BTB T
2Dennis LYL Y
3Li XTX T
4Whelan RDR D

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
Colony-Forming Units AssayMajor topic
DoxorubicinMajor topic
Tumor Stem Cell AssayMajor topic
Animals
Cell Line
Cricetinae
Drug Resistance
Humans
Mesocricetus
Naphthacenes

Source PubMed

Download CSV of topics

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16590531Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.Invest New Drugs1983https://conductscience.org/library/papers/6590531PubMed
26987066Lethal and kinetic effects of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine).Eur J Cancer (1965)1980https://conductscience.org/library/papers/6987066PubMed
3423191Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues.J Med Chem1979https://conductscience.org/library/papers/423191PubMed
46538489Phase II study of 9-hydroxy-2N-methylellipticinium acetate.Eur J Cancer Clin Oncol1984https://conductscience.org/library/papers/6538489PubMed
57448758Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture.Cancer Res1981https://conductscience.org/library/papers/7448758PubMed
66590532Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors.Invest New Drugs1983https://conductscience.org/library/papers/6590532PubMed
77200828Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.Cancer Res1982https://conductscience.org/library/papers/7200828PubMed
97214352Activity of mitoxantrone in a human tumor cloning system.Cancer Res1981https://conductscience.org/library/papers/7214352PubMed
10287555Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents.Cancer Treat Rep1979https://conductscience.org/library/papers/287555PubMed
116678865Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.Invest New Drugs1983https://conductscience.org/library/papers/6678865PubMed
12986302The value of adriamycin in overcoming resistance to methotrexate in tissue culture.Eur J Cancer (1965)1976https://conductscience.org/library/papers/986302PubMed
13688281Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy.Cancer Treat Rep1978https://conductscience.org/library/papers/688281PubMed
14709555In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.Cancer Treat Rep1978https://conductscience.org/library/papers/709555PubMed
156936969Antileukemic activity of 4-demethoxydaunorubicin in mice.Tumori1980https://conductscience.org/library/papers/6936969PubMed
16144604Flow microfluorometric estimation of G1 and G2 chalone inhibition of the JB-1 tumour cell cycle in vitro.Exp Cell Res1977https://conductscience.org/library/papers/144604PubMed
177105379Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105379PubMed
18565251Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model.Cancer Res1978https://conductscience.org/library/papers/565251PubMed
1970600204'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.Cancer Res1982https://conductscience.org/library/papers/7060020PubMed
207105380Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105380PubMed
216946877Evaluation of new anthracycline analogs with the human tumor stem cell assay.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/6946877PubMed

See all 33 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
8422694Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8422694PubMed
8261573Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8261573PubMed
8099807Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.Br J Cancer1993https://conductscience.org/library/papers/8099807PubMed
7779709In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.Br J Cancer1995https://conductscience.org/library/papers/7779709PubMed
3730255Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.Br J Cancer1986https://conductscience.org/library/papers/3730255PubMed
37188179-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.Br J Cancer1986https://conductscience.org/library/papers/3718817PubMed
3621454Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3621454PubMed
3472676Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3472676PubMed
3459509The in vitro effects and cross-resistance patterns of some novel anthracyclines.Br J Cancer1986https://conductscience.org/library/papers/3459509PubMed
3011054Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells.Br J Cancer1986https://conductscience.org/library/papers/3011054PubMed
2574988In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).Br J Cancer1989https://conductscience.org/library/papers/2574988PubMed
2547527
Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2547527PubMed
2337680Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil.Blut1990https://conductscience.org/library/papers/2337680PubMed
2311171DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2311171PubMed
1973363Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/1973363PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3858013

GET https://conductscience.org/api/papers/v1/3858013/references?page=2